Bone Mineral Density News and Research

RSS

Acceleron announces ACE-031 Phase 1b study results

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.

14 Oct 2010

New 2010 clinical practice guidelines for diagnosis and management of osteoporosis in Canada released

Today, Osteoporosis Canada released its 2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada, published in the Canadian Medical Association Journal. The new guidelines represent a paradigm shift in the prevention and treatment of osteoporotic fractures, moving the focus from treating low bone mineral density (BMD) to better identifying fractures caused by weakened bones (fragility fractures).

12 Oct 2010

Tips to keep bones strong

October 20 is World Osteoporosis Day. Most people know that osteoporosis is a condition that affects many older women. Though osteoporosis isn't as common in men -- because most men have naturally larger and stronger bones -- they can get it, too.

11 Oct 2010

Clinical study data on Natural S-equol supplement presented at NAMS Annual Meeting

Four clinical studies that add to the evidence about the use of a new nutritional supplement containing the whole soy germ-based ingredient Natural S-equol to improve health were presented at the North American Menopause Society (NAMS) Annual Meeting.

8 Oct 2010

$LIPUS ultrasound can speed fracture healing$

LIPUS ultrasound can speed fracture healing

Ultrasound can speed the healing of fractures. A randomized controlled trial reported in the open access journal BMC Musculoskeletal Disorders has found that the use of low-intensity pulsed ultrasound (LIPUS) in patients with tibial fractures which showed inadequate progress toward healing resulted in 34% greater bone mineral density (BMD) in the fracture area after 16 weeks than use of a sham device.

8 Oct 2010

Soy germ-based nutritional supplement helps to manage menopausal symptoms

A new women-s health, whole soy germ-based nutritional supplement containing Natural S-equol reduced the frequency of moderate to severe hot flashes and reduced muscle and joint pain in the first study of its kind among postmenopausal U.S. women, according to peer-reviewed data presented as a poster presentation at the North American Menopause Society (NAMS) Annual Meeting.

7 Oct 2010

Vitamin D supplementation in healthy kids pointless: Study

According to a Cochrane Systematic Review released on October 6th, yesterday vitamin D supplements when given to healthy children with normal vitamin D levels does not improve bone density at the hip, lumbar spine, forearm or in the body as a whole.

6 Oct 2010

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Using novel technology allowing "virtual bone biopsies" researchers have found that a common treatment for prostate cancer called androgen deprivation therapy (ADT) is associated with structural decay of cortical and trabecular bone. The study has been accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

6 Oct 2010

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck's request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

5 Oct 2010

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

14 Sep 2010

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Gilead Sciences, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for marketing approval for the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil (as fumarate)) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine (as hydrochloride)) for the treatment of HIV-1 infection in adults.

3 Sep 2010

Polyphenols affect nutrient absorption: Study

Health benefits from polyphenol antioxidants - substances found in many fruits and vegetables - may come at a cost to some people. Penn State nutritional scientists found that eating certain polyphenols decreased the amount of iron the body absorbs, which can increase the risk of developing an iron deficiency.

24 Aug 2010

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

23 Aug 2010

Study finds occurrence of low BMD in inflammatory bowel disease patients

A thesis from the University of Gothenburg (Sweden) is the first in Scandinavia to study the occurrence of low bone mineral density in children and teenagers with inflammatory bowel disease. Half of the patients in the study showed signs of low bone mineral density.

23 Aug 2010

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

SRI International, an independent nonprofit research and development organization, announced today that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company. Further clinical development will focus on the lead compound's registration for the treatment of tamoxifen and aromatase inhibitor-resistant breast cancers.

20 Aug 2010

New research explores effects of radiation on human bone after stereotactic radiosurgery

New research holds promise for the thousands of people whose cancer has spread to their bones.A common treatment for such patients is radiation surgery even though very little is known about radiosurgery's impact on bone strength, says Edmond Richer, associate professor of engineering at Southern Methodist University in Dallas.

18 Aug 2010

Study finds low carbohydrate diet may help improve cardiovascular risk factors

The effectiveness of a low-carbohydrate diet versus a low-fat diet for weight loss have been frequently debated. According to a new study published in Annals of Internal Medicine, both diets produce identical weight loss when coupled with comprehensive behavior treatment, but a low-carbohydrate diet may help improve cardiovascular risk factors.

3 Aug 2010

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Osteologix, Inc. through its wholly owned Irish subsidiary Osteologix Limited and the Servier Research Group, the leading French independent pharmaceutical company, today announced that Osteologix has granted Servier an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. NB S101 is an innovative molecule acting on both bone formation and bone resorption.

2 Aug 2010

Aggressive prostate cancer patients tend to retain denser bones

Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.

29 Jul 2010

Repros granted IRB approval to commence low dose Proellex study

Repros Therapeutics Inc. today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.

22 Jul 2010